AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-46 (Canceled)

47. (Currently Amended) A method for treating Parkinson's Disease, comprising stereotaxically administering into the central nervous system of ~~to~~ a Parkinson's disease patient an implant, wherein the implant comprises an extracellular matrix and human cells infected by a replication defective, recombinant adenovirus comprising a DNA sequence which encodes an intracellular, human CuZn superoxide dismutase-1 (SOD-1), wherein the DNA sequence is under the control of a signal enabling expression in a target cell and wherein said expression of said superoxide dismutase results in a treatment of Parkinson's disease.

Claims 48-60 (Canceled)

61. (Previously Presented) The method of treatment according to claim 47, wherein the DNA sequence is a cDNA sequence.

Claim 62 (Canceled)

63. (Previously Presented) The method of treatment according to claim 47, wherein the signal enabling expression in a target cell is a viral promoter.

64. (Previously Presented) The method of treatment according to claim 63, wherein the promoter is selected from the group consisting of the E1A, MLP, CMV and RSV-LTR promoters.

65. (Previously Presented) The method of treatment according to claim 47, wherein the adenovirus lacks regions of its genome which are necessary for replication in a target cell.

66. (Previously Presented) The method of treatment according to claim 47, wherein the adenovirus comprises ITR sequences and an encapsidation sequence, and wherein the E1 gene and at least one of the E2, E4 or L1-L5 genes are non-functional.

67. (Previously Presented) The method of treatment according to claim 47, wherein the adenovirus is of a type selected from the group consisting of human Ad 2, human Ad 5, and canine CAV-2.

68. (Previously Presented) The method of treatment according to claim 62, wherein the cDNA sequence encodes human intracellular CuZn superoxide dismutase-1 (hSOD1) under the control of an RSV-LTR promoter.

Claims 69-77 (Canceled)

78. (Previously Presented) The method of treatment according to claim 47, wherein the signal enabling expression in a target cell is a promoter permitting preponderant expression in the target cell.

79. (Previously Presented) The method of treatment according to claim 47, wherein the method comprises administering a cell infected with the replication defective, recombinant adenovirus to the patient.

Claims 80-82 (Canceled)

83. (Previously Presented) The method of treatment according to claim 66, wherein the adenovirus comprises ITR sequences and an encapsidation sequence, and wherein the E1 gene and at least one of the E4 or L1-L5 genes are non-functional.